Your browser doesn't support javascript.
loading
Research progress in immune checkpoint inhibitors in the treatment of oncogenedriven advanced nonsmall cell lung cancer / 中南大学学报(医学版)
Journal of Central South University(Medical Sciences) ; (12): 418-425, 2020.
Article in English | WPRIM | ID: wpr-827425
ABSTRACT
The clinical application of immune checkpoint inhibitors (ICIs) lead to dramatic changes in the treatment strategy for patients with advanced non-small cell lung cancer (NSCLC), but the efficacy of ICIs in oncogene-driven NSCLC is controversial. Existing research shows that the efficacy of ICIs may be related to different types of driver genes, programmed cell death-ligand 1 (PD-L1) level, and tumor mutational burden (TMB). It may involved in other factors, such as clinical characteristics, and immune cell density. ICIs monotherapy or combination therapy may play a role in a subset of oncogene-driven NSCLC patients, but further studies are needed to select these patients, which may be an important direction for the future development of advanced NSCLC.
Subject(s)

Full text: Available Index: WPRIM (Western Pacific) Main subject: Biomarkers, Tumor / Carcinoma, Non-Small-Cell Lung / Drug Therapy / B7-H1 Antigen / Genetics / Immunotherapy / Lung Neoplasms Limits: Humans Language: English Journal: Journal of Central South University(Medical Sciences) Year: 2020 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Biomarkers, Tumor / Carcinoma, Non-Small-Cell Lung / Drug Therapy / B7-H1 Antigen / Genetics / Immunotherapy / Lung Neoplasms Limits: Humans Language: English Journal: Journal of Central South University(Medical Sciences) Year: 2020 Type: Article